By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Luc Therapeutics 



Cambridge  Massachusetts    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS

Luc (pronounced ‘Luke’) Therapeutics – formerly Mnemosyne Pharmaceuticals – is a private, Cambridge, MA-based biotechnology company dedicated to discovering and developing medicines for patients living with serious psychiatric diseases. The company combines deep expertise in the pharmacology of NMDA receptors – critical modulators of the brain’s plasticity – and small molecule drug discovery leadership with recently discovered, yet validated, translational biomarkers. Luc believes this approach will more effectively and efficiently create new medicines for patients underserved by those available today. Luc’s negative allosteric modulator program has been licensed to Novartis for development of a fast-acting treatment for depression and, potentially, other diseases. Luc’s in-house discovery efforts focus on agents for addressing cognitive impairment in schizophrenia and other serious psychiatric diseases through positive allosteric modulation of the NMDA receptor (NMDA-PAMs). Luc’s investors include Atlas Venture, CLAL Biotechnology Industries (CBI, formerly Access BridgeGap Ventures) and Slater Technology Fund.

YEAR FOUNDED:

2010

LEADERSHIP:

CEO: Vanessa King

CSO: Tim Piser

FOLLOW LUC THERAPEUTICS:



Key Statistics


Email:
Ownership: Private

Web Site: Luc Therapeutics
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
//-->